Clinical trials: Resistant Major Depression, open to volunteers
Magnetic Resonance Imaging, Major Depression
Ketamine Alcohol (in Treatment-Resistant Depression)
A single subanesthetic dose infusion of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and robust antidepressant effects in patients with treatment-refractory major depressive disorder (TRD).
- Conditions
- Magnetic Resonance Imaging, Major Depression, Alcoholism
- Trial name
- NCT02122562
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mark Niciu
Treatment Resistant Depression, Major Depressive Disorder (MDD)
Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression
The goal of this clinical trial is to see if combining ketamine with behavioral activation (BA) therapy to treat moderate to severe treatment-resistant depression improves depressive symptoms and general functioning more than…
- Trial name
- NCT07801703
- Testing
- Ketamine (0.5 mg/kg), Behavioural Activation Therapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- The Royal's Institute of Mental Health Research
Major Depressive Disorder
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
The objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of the Motif eXternally powered Cortical Stimulation (XCS) System when used as indicated for treatment-resistant depression (TRD).
- Trial name
- RESONATE (NCT07594483)
- Testing
- Motif XCS System
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Motif Neurotech, Inc.
Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD)
Cannabidiol Oil for Treatment-Resistant Major Depression
Major depressive disorder is one of the leading causes of disability worldwide, and a substantial proportion of patients do not achieve adequate improvement with conventional antidepressant treatments.
- Trial name
- ANANDA (NCT07696871)
- Testing
- Full-spectrum CBD oil 100 mg/mL
- Where
- Brazil
- Volunteers
- 120 people
- Sponsor
- Universidade do Sul de Santa Catarina
Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms)
Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression
DECIDE- Deep phenotyping for clinical inferring response in treatment resistant depression -Study Building upon the "Biobanking" initiative at the Max Planck Institute of Psychiatry, the present project aims to identify…
- Conditions
- Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms), Depressive Disorder, Major, Recurrent, With Psychotic Symptoms, Depressive Disorder, Major, Recurrent, Without Psychotic Symptoms
- Trial name
- DECIDE (NCT06396312)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Major Depressive Disorder, Treatment Resistant Depression
40 Hz Light Neurostimulation for Patients With Depression (FELIX)
Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory.
- Trial name
- NCT05680220
- Testing
- Neurostimulation System (NSS): Active Setting
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Klaus Martiny
Bipolar II Disorder, Bipolar II Disorder, Most Recent Episode Major Depressive
Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression
Neurons are specialized types of cells that are responsible for carrying out the functions of the brain. Neurons communicate with electrical signals. In diseases such as major depression this electrical communication can go awry.
- Trial name
- PReSiDio-BP (NCT07127913)
- Testing
- Device: Stimulation-ON, Device: Stimulation-OFF, Device: Stimulation -ON Active Control
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Andrew Krystal
Obesity, Major Depressive Disorder
Comorbid Obesity and Depression With an Anti-inflammatory Medication
Research suggests that only a subset of individuals with major depressive disorder (MDD) may benefit from anti-inflammatory treatments: those who have C-reactive protein (CRP) ≥3 mg/L, a commonly used threshold for "low-grade"…
- Conditions
- Obesity, Major Depressive Disorder, Inflammation
- Trial name
- CODA (NCT06537921)
- Testing
- Minocycline 200mg
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- King's College London
Depression - Major Depressive Disorder, Treatment Resistant Depression
ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major Depressive Disorder
This research explores the potential of retinal ganglion cells (RGCs), particularly intrinsically photosensitive RGCs (ipRGCs), as biomarkers for predicting response to transcranial magnetic stimulation (TMS) in…
- Trial name
- BRIGHT (NCT07474974)
- Testing
- Repetitive transcranial magnetic stimulation (rTMS)
- Where
- Portugal
- Volunteers
- 44 people
- Sponsor
- Polytechnic Institute of Porto
Treatment Resistant Depression, Major Depressive Disorder
Biomarker-guided rTMS for Treatment Resistant Depression
Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. The investigators are continuing to learn how to optimize outcomes from rTMS treatment.
- Trial name
- BioTMS (NCT04041479)
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- 2 sites in United States
- Volunteers
- 348 people
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder (MDD)
Accelerated Neuromodulation of Anterior Cingulate Cortex for Depression
The goal of this clinical trial is to test whether an accelerated deep Transcranial Magnetic Stimulation (dTMS) protocol can reduce depressive symptoms in older adults (ages 60-85) with Major Depressive Disorder (MDD) who have…
- Trial name
- NACC-D (NCT07212465)
- Testing
- Active Brainsway H7-Coil Deep TMS System
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Rotman Research Institute at Baycrest
MDD, Severe Depression
Sensation Seeking and TMS Response in TRD
his real-world observational study examines whether sensation-seeking personality traits influence the clinical response to transcranial magnetic stimulation (TMS) in patients with treatment-resistant depression (TRD).
- Conditions
- MDD, Severe Depression, Major Depressive Episode
- Trial name
- NCT07889739
- Testing
- Transcranial Magnetic Stimulation (TMS)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Technical University of Munich
Depression, Depressive Disorder, Major
Comparing the Efficacy of Accelerated vs. Standard fMRI-guided iTBS in Treating Adolescents Depression
Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Theta burst stimulation (TBS), a type of rTMS, is a very promising new treatment for major depression in adults and…
- Trial name
- NCT06528938
- Testing
- Theta Burst Stimulation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Treatment-resistant Depression, Major Depressive Disorder
Physical Activity Program for TRD
This is a pilot study examining the delivery of a remotely delivered, one-on-one, individualized physical activity (PA) program in adult participants with treatment-resistant depression (TRD).
- Trial name
- NCT06404320
- Testing
- PA program - MoveU.HappyU
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Unity Health Toronto
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Accelerated iTBS for Major Depression
Major depressive disorder (MDD) is a common and disabling psychiatric condition, and many patients do not achieve adequate response to standard antidepressant treatments.
- Trial name
- AIM-D (NCT07603804)
- Testing
- Accelerated Intermittent Theta Burst Stimulation (iTBS)
- Where
- Turkey (Türkiye)
- Volunteers
- 35 people
- Sponsor
- Istanbul University - Cerrahpasa
Major Depressive Disorder
5-HTP and Creatine for Depression R33 Phase
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression.
- Trial name
- NCT05895747
- Testing
- Low Dose 5-hydroxytryptophan, High Dose 5-hydroxytryptophan, Low Dose Creatine Monohydrate
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- University of Utah
Major Depressive Disorder
RESISTance Exercise for Depression Trial
Depression is a leading cause of disability worldwide and current treatments are ineffective for many people. This trial will investigate the efficacy of a 16-week high vs low dose resistance exercise training program for the…
- Trial name
- RESIST (NCT06110897)
- Testing
- High Dose Resistance Exercise Training, Low Dose Resistance Exercise Training Group
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of Wisconsin, Madison
Depressive Disorder
Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients
Phase III, open label, randomised, multicentre, blind for evaluators clinical trial to evaluate the efficacy of esketamine nasal spray at flexible dosis compared to aripiprazole in elderly participants (>60 years) who suffer from…
- Trial name
- CESAR (NCT07153406)
- Testing
- Experimental regimen, Control regimen
- Where
- 9 sites in Spain
- Volunteers
- 220 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Feasibility Trial of Exercise as a Priming Strategy for rTMS Treatment in Difficult-to-Treat Depression
The goal of this study is to collect feasibility data on combining structured exercise aimed to improve physical fitness, and intermittent TBS (iTBS) in treating individuals diagnosed with difficult-to-treat depression who are…
- Trial name
- NCT06773949
- Testing
- Theta burst stimulation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Depression, Major Depressive Disorder
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Background: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work.
- Conditions
- Depression, Major Depressive Disorder, Major Depression
- Trial name
- NCT03973268
- Testing
- Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Mental Health (NIMH)